(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 January 2009 (22.01.2009)

PCT

(10) International Publication Number
WO 2009/010529 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61K 31/4418* (2006.01)
A61P 29/00 (2006.01) *A61K 31/517* (2006.01)

(21) International Application Number:
PCT/EP2008/059296

(22) International Filing Date: 16 July 2008 (16.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07112679.1 18 July 2007 (18.07.2007) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **FOX, Alyson** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **NASH, Mark** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **SOHAL, Bindi** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **LILLEY, Elliot** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB).

(74) Agents: **VOEGELI-LANGE, Regina** et al.; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

WO 2009/010529 A1

(54) **Title:** SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS

(57) **Abstract:** A synergistic combination of a vanilloid receptor VR-1 antagonist and an NSAID or a pharmaceutically acceptable salt or solvate of either or both compounds thereof.